2. Academic Validation
  3. Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine

Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine

  • Cell Rep Med. 2023 Dec 19;4(12):101340. doi: 10.1016/j.xcrm.2023.101340.
Xiaochun Liu 1,  Beilei Xu 1,  Xiaoqiang Xu 2,  Zhifeng Wang 3,  Yang Luo 1,  Yingxia Gao 1,  Shiqi Ling 1,  Ao Wang 1,  Yuan Zhou 1,  Xiaokai Wang 4,  Sean Xiao Leng 5,  Wei Li 6,  Xu Yao 7
Affiliations

Affiliations

  • 1 Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China.
  • 2 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai 200040, China.
  • 3 01Life Institute, Shenzhen 518000, China.
  • 4 Department of Biomedical Engineering, City University of Hong Kong, Hong Kong 999077, China.
  • 5 Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Johns Hopkins Center on Aging and Immune Remodeling, Baltimore, MD, USA. Electronic address: [email protected].
  • 6 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai 200040, China. Electronic address: [email protected].
  • 7 Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China. Electronic address: [email protected].
PMID: 38118418 DOI: 10.1016/j.xcrm.2023.101340
Abstract

Allergen-specific immunotherapy (AIT) has shown beneficial effects against atopic dermatitis (AD); however, the mechanisms and parameters underlying the efficacy of AIT remain unclear. Here, we report that the community structure and function of the oral and gut microbiota are changed in patients with AD undergoing AIT. Transplantation of fecal microbiota from patients who respond well to AIT improves AD-like dermatitis in mice. The abundance of Brevundimonas vesicularis in the gut of AD patients has been found to be positively correlated with disease severity and is decreased following AIT. Furthermore, we find that B. vesicularis from the oral cavity might ectopically colonize the gut of AD patients. In AD model mice, meanwhile, B. vesicularis promotes the skewing of the Treg/Th17 balance toward Th17 polarization and attenuates the efficacy of ovalbumin-specific immunotherapy. Our findings provide potential strategies for the optimization of AIT for AD via the modulation of the gut microbiota.

Keywords

allergen-specific immunotherapy; atopic dermatitis; gut; microbiota; oral cavity.

Figures
Products